title: [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease].
abstract: Aspirin desensitization has established itself as an additional therapy option in the treatment of aspirin- exacerbated respiratory disease, recurrent chronic rhinosinusitis and nasal polyps. Inpatient treatment is strongly recommended due to the risk of life-threatening side effects. In addition, the necessary requirements, indications and contraindications should be carefully considered from a medicolegal perspective. A maintenance dose of 300 (-500) mg ASS is currently recommended. Indications include persisting symptoms despite intensive medical care and/or recurrent nasal polyps, leading to recurrent sinus operations and/or the need to take systemic corticosteroids in order to control nasal symptoms or asthma. If ASS intake is interrupted for more than 48 h, aspirin desensitization should be resumed to prevent renewed intolerance reactions.
authors.affiliation: Nasennebenhöhlen- und Schädelbasischirurgie, Traumatologie, HNO-Klinik, Städtisches Klinikum Karlsruhe, Moltkestr. 90, 76133, Karlsruhe, Deutschland. rainerweber@rainerweber.de
authors.forename: R
authors.initials: R
authors.lastname: Weber
authors.forename: A
authors.initials: A
authors.lastname: Trautmann
authors.forename: W
authors.initials: W
authors.lastname: Randerath
authors.forename: W
authors.initials: W
authors.lastname: Heppt
authors.forename: W
authors.initials: W
authors.lastname: Hosemann
mesh_terms: D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects*; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D012120:Respiration Disorders / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D001241:Aspirin